A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
Phase 4
Completed
- Conditions
- CHRONIC HEPATITIS B
- Registration Number
- NCT00354653
- Lead Sponsor
- ViiV Healthcare
- Brief Summary
The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic hepatitis has been well established.The evidence in HBeAg negative patients is limited. Limited sustained response was observed post-treatment following a one year treatment period. Whether these results can be applied to patients in Iran is uncertain. This study is therefore intended to further assess the efficacy profile after two years of open treatment in the adult Iranian population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Confirmed active liver disease due to Hepatitis B virus.
- Patients must have adequate blood & liver functions.
- Female patients of child-bearing potential must be non pregnant and willing to abstain from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication or be willing to consistently and correctly use an acceptable method of birth control.
- Patients who have serious concurrent illnesses other than hepatitis B like cancer, severe heart disease, uncontrolled diabetes mellitus or AIDS will not be eligible.
Exclusion Criteria
- Persons allergic to lamivudine or suffering from hepatitis C, D or E infection or taking alcohol will not be eligible.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Complete virologic response at Month 24 which is normalisation of alanine aminotransferase (ALT) and disappearance of HBV DNA by NAXCOR(brand name of a virus assay kit)
- Secondary Outcome Measures
Name Time Method Partial response, histological improvement (at 24 months). Sustained complete response, sustained partial response at 30 months.
Trial Locations
- Locations (1)
GSK Clinical Trials Call Center
🇮🇷Tehran, Iran, Islamic Republic of